Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 6, 2023 / RedChip Companies will air interviews with Knightscope, Inc. (NASDAQ:KSCP), Soligenix, Inc. (Nasdaq:SNGX), and Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) on The RedChip Small Stocks Big Money Show, a sponsored program on Bloomberg TV, this Saturday, October 7, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
佛羅里達州奧蘭多/ACCESSWIRE/2023 年 10 月 6 日/ RedChip Companies將於美國東部時間10月7日星期六晚上7點在彭博電視臺贊助的節目《紅籌股大錢秀》上播出對Knightscope, Inc.（納斯達克股票代碼：KSCP）、Soligenix, Inc.（納斯達克股票代碼：SNGX）和基因技術有限公司（澳大利亞證券交易所股票代碼：GTG）（納斯達克股票代碼：GENE）的採訪。據估計，彭博電視在美國有7300萬個家庭中播出。
Access the interviews in their entirety at:
訪問訪談的全部內容，請訪問：
- Knightscope:
- Soligenix:
- Genetic Technologies:
- Knightscope：
- Soligenix：
- 遺傳技術：
William Santana Li, CEO and Chairman of Knightscope, Inc., appears on the RedChip Small Stocks Big Money Show on Bloomberg TV to provide a corporate update. Knightscope is an advanced security technology company based in Silicon Valley that builds fully autonomous security robots that deter, detect, and report. The Company's groundbreaking technology has proven to help in fighting crime and providing security and public safety professionals unprecedented situational awareness. Knightscope's cost-effective security robots help secure the places you live, work, study and visit. The Company's long-term ambition is to make the United States of America the safest country in the world.
Knightscope, Inc. 首席執行官兼董事長威廉·桑塔納·李出現在彭博電視臺的RedChip Small Stocks Big Money Show上，提供了公司最新情況。Knightscope是一家總部位於硅谷的先進安全技術公司，致力於製造能夠阻止、檢測和報告的全自主安全機器人。事實證明，該公司的開創性技術有助於打擊犯罪，併爲安全和公共安全專業人員提供前所未有的態勢感知能力。Knightscope 經濟實惠的安全機器人可幫助保護您的生活、工作、學習和參觀場所。該公司的長期目標是使美利堅合衆國成爲世界上最安全的國家。
Also appearing on the RedChip Small Stocks Big Money Show this week is Dr. Chris Schaber, CEO of Soligenix. Soligenix, a late-stage biopharmaceutical company, offers a robust pipeline of multiple fast-track and orphan-designated products with the potential for significant commercial returns of approximately $2 billion in global annual sales. Soligenix's late-stage clinical assets include HyBryte (SGX301), a photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL). The positive statistically significant results achieved in the Phase 3 study of HyBryte have been published in JAMA Dermatology, and the Company is preparing to meet with the FDA to discuss the design of the second confirmatory Phase 3 study. The estimated global market potential for HyBryte is $250 million, making it a significant commercial opportunity in an area of unmet medical need.
Soligenix首席執行官克里斯·沙伯博士也出現在本週的RedChip Small Stocks Big Money Show上。Soligenix是一家處於後期階段的生物製藥公司，提供多種快速通道和孤兒指定產品的強大產品線，全球年銷售額有可能帶來約20億美元的可觀商業回報。Soligenix的後期臨床資產包括Hybryte（SGX301），這是一種用於治療皮膚T細胞淋巴瘤（CTCL）的光動力療法。HyBryte的3期研究中取得的具有統計學意義的積極結果已發表在《JAMA Dermatology》上，該公司正準備與美國食品藥品管理局會面，討論第二項確認性3期研究的設計。據估計，HyBryte的全球市場潛力爲2.5億美元，這使其成爲醫療需求未得到滿足的領域的重大商業機會。
The third interview is with Simon Morriss, CEO of Genetic Technologies. Genetic Technologies is executing a B2B commercialization strategy for its flagship geneType Multi-Risk test covering breast cancer, colorectal cancer, prostate cancer, ovarian cancer, coronary artery disease and Type-2 diabetes, a first-in-class test that can predict a person's risk in up to 70% of annual mortalities and morbidities before onset. Recently, the Company's assessments for Pancreatic Cancer, Melanoma, and Atrial Fibrillation, were authorized for sale in Australia by National Association of Testing Authority (NATA). Genetic Technologies also signed a precision medicine pilot with Gold Coast Private Hospital (GCPH), a member of Healthscope - Australia's largest private hospital network. Separately, the Company also recently announced a Medical Research Future Fund (MRFF) Genomics Health Futures Mission Grant has been awarded to a group of renowned national and international research and charity organizations. The grant will provide funding for the CASSOWARY Trial: a randomized controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice. GTG is the National Research Partner for trial.
第三次採訪是基因技術公司首席執行官西蒙·莫里斯。Genetic Technologies正在爲其旗艦GeneType多風險測試執行B2B商業化戰略，涵蓋乳腺癌、結直腸癌、前列腺癌、卵巢癌、冠狀動脈疾病和2型糖尿病，這是一項同類首創的測試，可以在發病前預測高達70％的年度死亡率和發病率。最近，該公司對胰腺癌、黑色素瘤和心房顫動的評估已獲得全國檢測機構協會（NATA）的批准在澳大利亞銷售。Genetic Technologies還與澳大利亞最大的私立醫院網絡Healthscope的成員黃金海岸私立醫院（GCPH）簽署了精準醫療試點協議。另外，該公司最近還宣佈，已向一羣著名的國內和國際研究和慈善組織發放了醫學研究未來基金（MRFF）基因組學健康未來使命補助金。這筆撥款將爲CASSOWARY試驗提供資金：一項隨機對照試驗，研究全科醫生中多癌症多基因風險評分的臨床效用和成本效益。GTG是試驗的國家研究合作伙伴。
About Knightscope, Inc.
關於 Knightscope, Inc.
Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope's long-term ambition is to make the United States of America the safest country in the world. Learn more about us at .
Knightscope是一家先進的公共安全技術公司，致力於製造全自主安全機器人和藍光應急通信系統，以幫助保護人們生活、工作、學習和參觀的地方。Knightscope的長期目標是使美利堅合衆國成爲世界上最安全的國家。要了解更多關於我們的信息，請訪問。
About Soligenix, Inc.
關於 Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203).
Soligenix是一家處於後期階段的生物製藥公司，專注於開發和商業化用於治療醫療需求未得到滿足的罕見疾病的產品。我們的專業生物治療業務部門正在開發Hybryte（SGX301 或合成金絲桃素鈉），並朝着潛在的商業化方向發展，這是一種利用安全可見光治療皮膚T細胞淋巴瘤（CTCL）的新型光動力療法。隨着一項3期研究的成功完成，該候選產品的商業化活動正在尋求監管部門的批准，該候選產品的商業化活動正在美國初步推進。該業務領域的開發計劃還包括將合成金絲桃素（SGX302）擴展到牛皮癬、我們的同類首創先天防禦調節劑（IDR）技術、用於治療炎症性疾病（包括頭頸部癌的口腔粘膜炎製劑）的杜斯克肽（SGX942）以及口服倍氯米司的專利用於預防的17,21-二丙酸酯 (BDP) 的松/治療以嚴重炎症爲特徵的胃腸道（GI）疾病，包括小兒克羅恩氏病（SGX203）。
Our Public Health Solutions business segment includes active development programs for RiVax, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
我們的公共衛生解決方案業務部門包括RivaX的積極開發計劃，我們的蓖麻毒素候選疫苗，以及我們針對絲狀病毒（例如馬爾堡和埃博拉）的疫苗計劃以及我們預防 COVID-19（由 SARS-CoV-2 引起）的候選疫苗 civaX。我們的疫苗項目開發採用了我們專有的熱穩定平台技術，即 ThermoVax。迄今爲止，該業務領域得到了國家過敏和傳染病研究所（NIAID）、國防威脅減少局（DTRA）和生物醫學高級研究與發展局（BARDA）的政府補助和合同資金的支持。
For further information regarding Soligenix, Inc., please visit the Company's website at
有關 Soligenix, Inc. 的更多信息，請訪問該公司的網站
About Genetic Technologies Limited
關於基因技術有限公司
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit .
基因技術有限公司（澳大利亞證券交易所股票代碼：GTG；納斯達克：GENE）是一家多元化的分子診斷公司。憑藉其GeneType和easyDNA品牌，成爲健康、保健和嚴重疾病領域基於基因組學的檢測領域的全球領導者。GTG提供癌症預測測試和評估工具，以幫助醫生改善世界各地人們的健康狀況。該公司擁有一個專有的風險分層平台，該平台是在過去十年中開發的，該平台整合了臨床和遺傳風險，爲醫生和個人提供可行的結果。Genetic Technologies在腫瘤、心血管和代謝疾病的風險預測方面處於世界領先地位，繼續開發風險評估產品。欲了解更多信息，請訪問。
About RedChip Companies
關於紅籌公司
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Small Stocks Big Money Show is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Small Stocks Big Money Show," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Companies是一家Inc. 5000公司，是一家專注於微型股和小型股公司的國際投資者關係、媒體和研究公司。30年來，RedChip爲其客戶提供了具體、可衡量的結果。我們的時事通訊《RedChip Small Stocks Big Money Show》每週在線向6萬名投資者發佈。RedChip爲微型股和小型股公司開發了業內最全面的服務平台。這些服務包括：股票研究的全球分銷網絡；美國主要城市的零售和機構路演；股票經紀商、區域投資協議、機構和家族辦公室的境外營銷；產生數百萬獨特投資者觀點的數字媒體投資者關係平台；投資者網絡研討會和羣組電話會議；每週在美國彭博社播出的電視節目 “紅籌小股大額資金秀”；本地和全國市場的電視廣告；公司產品和視頻；網站設計；以及傳統投資者關係服務，包括撰寫新聞稿、撰寫投資者簡報、撰寫季度電話會議劇本、戰略諮詢、融資等。
To learn more about RedChip's products and services, please visit:
要了解有關RedChip產品和服務的更多信息，請訪問：
"Discovering Tomorrow's Blue Chips Today"
“今天發現明天的藍籌股”
Follow RedChip on LinkedIn:
在領英上關注 RedChip：
Follow RedChip on Facebook:
在臉書上關注 RedChip：
Follow RedChip on Instagram:
在 Instagram 上關注 RedChip
Follow RedChip on Twitter:
在推特上關注 RedChip：
Follow RedChip on YouTube:
在 YouTube 上關注 RedChip
Follow RedChip on Rumble:
在 Rumble 上關注 RedChip：
Subscribe to our Mailing List:
訂閱我們的郵件列表：
Contact:
聯繫人：
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
info@redchip.com
戴夫·金特里
RedChip Companies
1-800-RED-CHIP (733-2447)
或 407-491-4498
info@redchip.com
SOURCE: RedChip
來源： redChip
譯文內容由第三人軟體翻譯。